Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-rwnhh Total loading time: 0 Render date: 2025-03-01T13:53:15.805Z Has data issue: false hasContentIssue false

Chapter 10 - Myeloproliferative Neoplasms

Published online by Cambridge University Press:  12 November 2020

Jon van der Walt ,
Attilio Orazi  and
Daniel A. Arber
By
Hans Michael Kvasnicka  and
Attilio Orazi
Jon van der Walt
Affiliation:
St Thomas’ Hospital, London
Attilio Orazi
Affiliation:
Texas Tech University
Daniel A. Arber
Affiliation:
University of Chicago
Get access

Summary

The ‘classical’ Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), essential thrombocythaemia (ET), primary myelofibrosis (PMF) and polycythaemia vera (PV), are characterized by clonal myeloproliferation with effective maturation causing accumulation of terminally differentiated cells in the peripheral blood and/or splenomegaly. Although each disease has distinct clinical manifestations clonal haematopoiesis is driven, in most cases, by upregulation of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway [1]. Polycythaemia vera and ET are relatively indolent, with most patients having nearly normal life expectancy, in contrast to PMF [2]. Thrombosis and haemorrhage are the main causes of morbidity and mortality in both PV and ET, and evolution to myelofibrosis (MF) and/or accelerated/blast phase (AP/BP) is estimated to occur in 10% of patients [3, 4]. Overt (classical) PMF is the most aggressive of the three diseases, with a median overall survival of five years. The most common causes of mortality are transformation to BP (20 to 25% of patients), thrombosis, cardiovascular complications and infections [5]. However, it is important to note that incidence figures, survival and also risk-factor determinations may be inaccurate and at times conflicting because of the inadvertent labelling in some studies of patients with prefibrotic/early PMF (prePMF) or ‘masked’(prodromal) PV as ET [6–8].

Type
Chapter
Information
Diagnostic Bone Marrow Haematopathology , pp. 146 - 161
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Nangalia, J, Green, AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130(23):2475–83.Google Scholar
Arber, DA, Orazi, A, Hasserjian, R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.CrossRefGoogle Scholar
Tefferi, A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(12):1551–60.CrossRefGoogle ScholarPubMed
Tefferi, A, Barbui, T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94(1):133–43.Google Scholar
Mesa, RA, Verstovsek, S, Cervantes, F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737–40.Google Scholar
Kvasnicka, HM. WHO classification of myeloproliferative neoplasms (MPN): a critical update. Curr Hematol Malig Rep. 2013;8(4):333–41.CrossRefGoogle ScholarPubMed
Kvasnicka, HM, Thiele, J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32(4):362–71.Google Scholar
Kvasnicka, HM, Thiele, J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010;85(1):62–9.Google Scholar
Mejia-Ochoa, M, Acevedo Toro, PA, Cardona-Arias, JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019;19(1):590.Google Scholar
Barbui, T, De Stefano, V, Falanga, A, et al. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: a consensus-based position paper. Blood Cancer J. 2019;9(8):61.Google Scholar
Barbui, T, Thiele, J, Gisslinger, H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.CrossRefGoogle ScholarPubMed
Thiele, J, Kvasnicka, HM, Diehl, V. Standardization of bone marrow features: does it work in haematopathology for histological discrimination of different disease patterns? Histol Histopathol. 2005;20(2):633–44.Google Scholar
Thiele, J, Kvasnicka, HM, Orazi, A. Bone marrow histopathology in myeloproliferative disorders: current diagnostic approach. Semin Hematol. 2005;42(4):184–95.CrossRefGoogle ScholarPubMed
De Stefano, V, Fiorini, A, Rossi, E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5(4):708–14.CrossRefGoogle ScholarPubMed
Thiele, J, Kvasnicka, HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost. 2006;32(3):219–30.Google Scholar
Carobbio, A, Thiele, J, Passamonti, F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–9.Google Scholar
Finazzi, G, De Stefano, V, Barbui, T. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer J. 2018;8(7):64.Google Scholar
Madelung, AB, Bondo, H, Stamp, I, et al. World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations. The Danish experience. Am J Hematol. 2013;88(12):1012–16.CrossRefGoogle ScholarPubMed
Kvasnicka, HM, Thiele, J. Classification of Ph-negative chronic myeloproliferative disorders: morphology as the yardstick of classification. Pathobiology. 2007;74(2):63–71.CrossRefGoogle ScholarPubMed
Barbui, T, Thiele, J, Passamonti, F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1,104 patients. J Clin Oncol. 2011;29(23):3179–84.Google Scholar
Buxhofer-Ausch, V, Gisslinger, H, Thiele, J, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol. 2012;87(7):669–72.CrossRefGoogle Scholar
Zini, R, Guglielmelli, P, Pietra, D, et al. CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer J. 2017;7(12):638.Google Scholar
Agarwal, R, Blombery, P, McBean, M, et al. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. Ann Hematol. 2017;96(5):725–32.CrossRefGoogle ScholarPubMed
Schischlik, F, Kralovics, R. Mutations in myeloproliferative neoplasms: their significance and clinical use. Expert Rev Hematol. 2017;10(11):961–73.CrossRefGoogle ScholarPubMed
Masarova, L, Alhuraiji, A, Bose, P, et al. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018;100(3):257–63.Google Scholar
Thiele, J, Kvasnicka, HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85(4):226–32.Google Scholar
Boiocchi, L, Espinal-Witter, R, Geyer, JT, et al. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol. 2013;26(2):204–12.Google Scholar
Czader, M, Orazi, A. Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms. Am J Clin Pathol. 2015;144(2):188–206.Google Scholar
Thiele, J, Kvasnicka, HM. Myelofibrosis in chronic myeloproliferative disorders: dynamics and clinical impact. Histol Histopathol. 2006;21(12):1367–78.Google Scholar
Thiele, J, Kvasnicka, HM, Facchetti, F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–32.Google ScholarPubMed
Mesa, RA, Hanson, CA, Rajkumar, SV, Schroeder, G, Tefferi, A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96(10):3374–80.Google Scholar
Thiele, J, Kvasnicka, H. CD34(+) stem cells in chronic myeloproliferative disorders. Histol Histopathol. 2002;17(2):507–21.Google Scholar
Thiele, J, Kvasnicka, HM, Vardiman, J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19(3):413–37.Google Scholar
Geyer, JT, Margolskee, E, Krichevsky, SA, et al. Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica. 2020;105(5):e221–e224.Google Scholar
Szuber, N, Mudireddy, M, Nicolosi, M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94(4):599–610.Google Scholar
Guglielmelli, P, Lasho, TL, Rotunno, G, et al. MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310–18.Google Scholar
Kuykendall, AT, Talati, C, Padron, E, et al. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019;94(1):87–92.Google Scholar
Kvasnicka, HM, Beham-Schmid, C, Bob, R, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis: a consensus-based study. Histopathology. 2016;68(6):905–15.CrossRefGoogle ScholarPubMed
Barbui, T, Thiele, J, Carobbio, A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014;89(2):199–202.CrossRefGoogle ScholarPubMed
Barbui, T, Thiele, J, Gisslinger, H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89(1):52–4.Google Scholar
Boiocchi, L, Mathew, S, Gianelli, U, et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. Mod Pathol. 2013;26(12):1577–85.CrossRefGoogle ScholarPubMed
Masarova, L, Bose, P, Daver, N, et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017;59:110–16.Google Scholar
Mora, B, Giorgino, T, Guglielmelli, P, et al. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018;103(9):e392–e4.Google Scholar
Silver, RT, Chow, W, Orazi, A, Arles, SP, Goldsmith, SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013;122(11):1881–6.Google Scholar
Thiele, J, Kvasnicka, H. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol. 2005;20(1):317–28.Google Scholar
Thiele, J, Kvasnicka, H, Diehl, V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematologica. 2005;113(4):213–19.Google Scholar
Barbui, T, Thiele, J, Passamonti, F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119(10):2239–41.Google Scholar
Boiocchi, L, Gianelli, U, Iurlo, A, et al. Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications. Mod Pathol. 2015;28(11):1448–57.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×